Webcast/CME - Clinical Experience with Vorinostat in CTCL and Sézary Syndrome

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Dermatology Other

EXPLORE :

Most Read News

All Webcasts / CME

Warning | Privacy

Recent webcasts/CME - Dermatology Other

	Advancements in Enzymatic Debridement: Applying Clinical Science to Everyday Applications
	The Prevention and Treatment of Pressure Ulcers
	Contemporary Options for the Management of Scars
	Pediatric and Adolescent Sports-Related Injuries and Ailments
	The Wound Healing Process

Recent news - Dermatology Other

	Blood Flow Cytometry May Be Preferable Way to Diagnose, Analyse Mycosis Fungoides: Presented at ASCP - (DGDispatch)
	Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
	Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
	Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)
	Mycophenolate Mofetil Benefits Patients With Pemphigus Vulgaris: Presented at EADV - (DGDispatch)

Recent cases - Dermatology Other

	Something Fishy
	Russell Bodies in a Skin Biopsy: A Case Report
	Yellow Nail Syndrome
	Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
	Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)

personal edition > dermatology other > webcasts/CME

Webcasts/CME

E-Mail this webcast/CME to a colleague

Clinical Experience with Vorinostat in CTCL and Sézary Syndrome

Presented by:	The University of Kentucky College of Medicine
Lecturer	Francine Foss, MD
Approximate duration:	Not available
Summary points:	This audiovisual presentation discusses the classifications of cutaneous T-cell lymphoma and Sézary syndrome, the epidemiology and aetiology of mycosis fungoides, disease-specific survival rates, clinical responses to various therapies and immunotherapy, treatment of advanced stage/refractory patients, data from the Depsipeptide Phase 2 study, and evidence from clinical trials of vorinostat, known drug-related adverse effects.
Accreditation:	The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The University of Kentucky College of Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits. Expiration date: January 1, 2007.
Other:

Additional Information